Flu Vaccine

BIOLOGICAL7 trials

Sponsors

La Fundacion Favaloro para la Investigacion y la Docencia Medica, Emory University, Health Sciences North Research Institute, GlaxoSmithKline, Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions

Cost-Benefit AnalysisElderly Immune SystemFlu VaccineHeart FailureImmunosuppressionInfluenzaInfluenza VaccineRespiratory Syncytial Virus Infections

Phase 3

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

CompletedNCT05568797

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2022-10-14End: 2023-07-17Updated: 2024-09-24

Phase 4

Flu Vaccination in Congestive Heart Failure

CompletedNCT00664339

La Fundacion Favaloro para la Investigacion y la Docencia MedicaHeart Failure

Start: 2007-05-31End: 2008-03-31Updated: 2008-04-22

Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

Health Sciences North Research InstituteElderly Immune System

Start: 2014-10-31End: 2019-12-31Target: 85Updated: 2018-08-01

Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses

Active, not recruitingNCT06824779

Centre Hospitalier Universitaire de Saint EtienneFlu Vaccine, Volunteers

Start: 2025-12-05End: 2026-03-31Updated: 2025-12-30

Unknown Phase

Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression

CompletedNCT01733056

Emory UniversityImmunosuppression

Start: 2011-01-31End: 2013-01-31Updated: 2014-07-21

Protection From Influenza: Determining the Impact of Prior Infection

Health Sciences North Research InstituteInfluenza

Start: 2016-12-31End: 2019-01-31Target: 50Updated: 2018-02-23

Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome

CompletedNCT06304038

Fondazione Policlinico Universitario Agostino Gemelli IRCCSCost-Benefit Analysis, Influenza Vaccine

Start: 2017-10-16End: 2019-11-14Updated: 2024-03-12

Related Papers

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Clinical Infectious Diseases2024-08-0514 citations

Key Determinants of Cell-Mediated Immune Responses: A Randomized Trial of High Dose Vs. Standard Dose Split-Virus Influenza Vaccine in Older Adults

Frontiers in Aging2021-05-219 citations